Tech Company Financing Transactions

MaxCyte Funding Round

Private investors participated in a $760.3 thousand capital raise for MaxCyte. This venture round was announced on 9/30/2016.

Transaction Overview

Company Name
Announced On
9/30/2016
Transaction Type
Venture Equity
Amount
$760,308
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 9 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
22 Firstfield Rd. 110
Gaithersburg, MD 20878
USA
Email Address
Overview
MaxCyte is a clinical-stage cell therapeutics company with a growing pipeline of proprietary and partnered drug candidates.
Profile
MaxCyte LinkedIn Company Profile
Social Media
MaxCyte Company Twitter Account
Company News
MaxCyte News
Facebook
MaxCyte on Facebook
YouTube
MaxCyte on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Douglas Doerfler
  Douglas Doerfler LinkedIn Profile  Douglas Doerfler Twitter Account  Douglas Doerfler News  Douglas Doerfler on Facebook
Chief Financial Officer
Ronald Holtz
  Ronald Holtz LinkedIn Profile  Ronald Holtz Twitter Account  Ronald Holtz News  Ronald Holtz on Facebook
Chief Medical Officer
Claudio Ullmann
  Claudio Ullmann LinkedIn Profile  Claudio Ullmann Twitter Account  Claudio Ullmann News  Claudio Ullmann on Facebook
VP - Customer Service
James Brady
  James Brady LinkedIn Profile  James Brady Twitter Account  James Brady News  James Brady on Facebook
VP - General Counsel
Maher Masoud
  Maher Masoud LinkedIn Profile  Maher Masoud Twitter Account  Maher Masoud News  Maher Masoud on Facebook
VP - Operations
Brad Calvin
  Brad Calvin LinkedIn Profile  Brad Calvin Twitter Account  Brad Calvin News  Brad Calvin on Facebook
VP - Regulatory Affairs
Kathryn Wekselman
  Kathryn Wekselman LinkedIn Profile  Kathryn Wekselman Twitter Account  Kathryn Wekselman News  Kathryn Wekselman on Facebook
VP - Sales
Thomas Ross
  Thomas Ross LinkedIn Profile  Thomas Ross Twitter Account  Thomas Ross News  Thomas Ross on Facebook


 

 

Browse more venture capital transactions:

Prev: 9/30/2016: Karamba Security venture capital transaction
Next: 9/30/2016: Lingumi venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary